Type 2 Diabetes

Researchers writing in Diabetes Care this month report that empagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2), successfully reduced liver fat content in recent-onset and metabolically well-controlled type 2 diabetes (T2D).

Medicaid expansion under the Patient Protection and Affordable Care Act (ACA) was associated with reduced uninsured rates in the diabetes belt compared with non-belt counties, say researchers writing in Diabetes Care.

New research from the American Stroke Association's International Stroke Conference indicates the presence of diabetic retinopathy was associated with increased stroke risk.

In post-myocardial infarction patients, chronically impaired renal failure and diabetes are both associated with an increased mortality risk, say researchers recently writing in Diabetes Care.

David Lee, MD, of NYU School of Medicine, discusses barbershop initiatives and how they can impact the health care of a community as a whole.

Offspring of severely obese mothers with insulin-treated pregestational diabetes are at an estimated 128% increased risk of being diagnosed with a psychiatric disorder.

A meta-analysis of CREDENCE, DECLARE-TIMI 58, CANVAS, and EMPA-REG OUTCOME trial is revealing more about how SGLT2 inhibition impacts different subgroups of diabetics.

Leading experts on nutrition and diabetes are recommending that patients still continue to follow current nutritional recommendations by the American Diabetes Association and other healthcare and governmental organizations that recommend consuming a diet rich in fruits and vegetables, while limiting red and processed meats.

An oral tablet combining empagliflozin, linagliptin, metformin hydrochloride will soon be available on US markets.

A new analysis of more than 125,000 found no differences in mortality or MACE based on type of insulin used.

The GLP-1 agonist now has indications for the reduction of MACE and the management of A1C in patients with type 2 diabetes.

A pilot study from the University of Warwick found sitagliptin, which is approved for glycemic control in diabetics, could be a promising treatment for reducing miscarriages in women with recurrent pregnancy loss.

The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.

The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.

Novo Nordisk announced the US FDA's approval of insulin aspart injection 100 u/mL (Fiasp) for glycemic control in children in a press release on Monday morning.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.

How women who undergo menopause before age 40 may be at a greater risk of heart disease.

Insulin resistance is independently associated with body mass index (BMI) and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.

The authorization could allow other technology for diabetes to go through the review process more quickly.

How technology, innovation, and preventive care drove the last 10 years of improved public heart health.

An analysis of more than 4 million patients in the Swedish Birth Registry is shining light on the associations between preterm birth and the development of diabetes as a child or young adult.

Results of a pilot study examining the impact of a 10-hour restricted eating window in patients with metabolic syndrome indicate the dietary intervention could help patients lose weight and improve their symptoms without changes in physical activity

Discussing why initiatives and policy changes in the fight against obesity and diabetes have been perceived as less successful than those against smoking and educating on cardiovascular diseases.

Evaluating the impact of DAPA-HF and other recent data that have changed the way cardiologists view the potential uses of SGLT2 inhibitors in patients with or without diabetes.